Form 4: Pharvaris Director Sells Shares Under 10b5-1 Plan

Pharvaris N.V. Director Johannes Schikan sold 2,400 shares of common stock for approximately $35.10 per share as part of a pre-arranged 10b5-1 trading plan.

Summary

• Johannes Schikan, a Director at Pharvaris N.V., reported the sale of 2,400 shares of common stock on June 29, 2026.
• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-arranged.
• The weighted average sale price was $35.10 per share, with individual transactions ranging from $35.00 to $35.30.
• Following these transactions, Mr. Schikan beneficially owns 352,767 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While a director's sale can be a negative signal, the execution under a Rule 10b5-1 plan mitigates concerns about insider trading and suggests a planned, rather than reactive, divestment.

Positives

• The sale was executed under a Rule 10b5-1 plan, which is designed to provide an affirmative defense against insider trading allegations by establishing a predetermined trading strategy.
• The transaction was a scheduled sale, suggesting a planned divestment rather than a reaction to adverse company news.

Negatives

• A director has sold a portion of their holdings, which could be perceived negatively by the market, although it was part of a pre-planned strategy.

Risks

• The filing does not explicitly mention any new risks. However, any sale of stock by a director can be interpreted by the market as a potential signal of reduced confidence, even if executed under a 10b5-1 plan.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports a change in beneficial ownership.

Management Comments

• The sale was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan.
• The sales prices for the transactions ranged from $35.00 to $35.30.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common in the biotechnology and pharmaceutical sectors, especially for executives and directors who may need to diversify their holdings or manage personal finances. While these plans are designed to mitigate insider trading concerns, significant sales can still influence market perception.

Stakeholder Impact

• Shareholders: May interpret the sale as a minor negative signal, though mitigated by the 10b5-1 plan. The continued beneficial ownership of 352,767 shares by the director suggests ongoing commitment.
• Employees: No direct impact indicated.
• Creditors: No direct impact indicated.
• Suppliers/Customers: No direct impact indicated.

Next Steps

• No specific next steps are outlined in this filing beyond the completion of the reported transaction.

Key Dates

Keywords

Pharvaris N.V., PHVS, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Director, Beneficial Ownership, Securities Exchange Act